MAPLE GROVE, Minn., Nov. 7, 2022 /PRNewswire/ — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has extended its line of Haloperidol Tablets, USP and is now offering unit dose packaging in 1 mg, 5 mg, and 10 mg strengths. The new packaging aims to expand supply options for dispensing pharmacies that utilize unit-dose packaged products. Upsher-Smith’s Haloperidol Tablets are also available in bottles of 100 tablets in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg strengths. Haloperidol Tablets are a generic version of the brand product, Haldol® Tablets*.
The haloperidol unit-dose tablet market had U.S. sales of approximately $9 million for the 12 months ending July 2022 according to IQVIA.
|Product||Strength||NDC #||Package Size|
|Haloperidol Tablets, USP||1 mg||0832-1520-01||100-count UD|
|Haloperidol Tablets, USP||5 mg||0832-1540-01||100-count UD|
|Haloperidol Tablets, USP||10 mg||0832-1550-01||100-count UD|
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please refer to the full Prescribing Information, including Boxed Warning for Haloperidol Tablets, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
*Haldol is a registered trademark of Johnson & Johnson Corp; Haldol Tablets have been discontinued.